BACKGROUND: The identification of biomarkers identifying onset of human immunodeficiency virus-associated dementia (HIV-D) is critical for diagnosis and the elucidation of pathophysiologic pathways. OBJECTIVE: To examine the association between platelet decline from baseline and HIV-D. DESIGN: Prospective cohort study within the North-East AIDS Dementia cohort. SETTING: Four participating referral centers in the United States. PARTICIPANTS: A total of 396 subjects with advanced human immunodeficiency virus (HIV) infection recruited between 1998 and 2003 and undergoing serial neurologic assessments. Eligibility criteria required CD4 cell counts less than 200/microL or less than 300/microL with evidence of cognitive impairment. A cohort subset without prevalent HIV-D at baseline and without incident HIV-D at the visit immediately after baseline was analyzed (n = 146). Main Outcome Measure Time to first diagnosis of HIV-D. RESULTS: After a median follow-up of 31.1 months, 40 subjects developed HIV-D. Platelet decline from baseline was associated with the development of HIV-D when examined as a time-dependent variable lagged by 6 to 12 months before outcome (multivariate hazard ratio [HR], 2.39; 95% confidence interval [CI], 1.14-5.02; P = .02). This association was stronger during the first 2 years of follow-up (multivariate HR, 6.76; 95% CI, 2.36-19.41; P < .001) than during later years (multivariate HR, 0.94; 95% CI, 0.33-2.67; P = .90). CONCLUSIONS: These results suggest that individuals with declining platelet counts are at greater risk for HIV-D and that the dynamics of circulating platelets vary with respect to the temporal progression of HIV-D. This highlights an avenue to be explored in the understanding of HIV-D pathogenesis.
BACKGROUND: The identification of biomarkers identifying onset of human immunodeficiency virus-associated dementia (HIV-D) is critical for diagnosis and the elucidation of pathophysiologic pathways. OBJECTIVE: To examine the association between platelet decline from baseline and HIV-D. DESIGN: Prospective cohort study within the North-East AIDS Dementia cohort. SETTING: Four participating referral centers in the United States. PARTICIPANTS: A total of 396 subjects with advanced human immunodeficiency virus (HIV) infection recruited between 1998 and 2003 and undergoing serial neurologic assessments. Eligibility criteria required CD4 cell counts less than 200/microL or less than 300/microL with evidence of cognitive impairment. A cohort subset without prevalent HIV-D at baseline and without incident HIV-D at the visit immediately after baseline was analyzed (n = 146). Main Outcome Measure Time to first diagnosis of HIV-D. RESULTS: After a median follow-up of 31.1 months, 40 subjects developed HIV-D. Platelet decline from baseline was associated with the development of HIV-D when examined as a time-dependent variable lagged by 6 to 12 months before outcome (multivariate hazard ratio [HR], 2.39; 95% confidence interval [CI], 1.14-5.02; P = .02). This association was stronger during the first 2 years of follow-up (multivariate HR, 6.76; 95% CI, 2.36-19.41; P < .001) than during later years (multivariate HR, 0.94; 95% CI, 0.33-2.67; P = .90). CONCLUSIONS: These results suggest that individuals with declining platelet counts are at greater risk for HIV-D and that the dynamics of circulating platelets vary with respect to the temporal progression of HIV-D. This highlights an avenue to be explored in the understanding of HIV-D pathogenesis.
Authors: Ann B Ragin; Gypsyamber D'Souza; Sandra Reynolds; Eric Miller; Ned Sacktor; Ola A Selnes; Eileen Martin; Barbara R Visscher; James T Becker Journal: J Neurovirol Date: 2011-09-29 Impact factor: 2.643
Authors: Robert C Kalayjian; Kunling Wu; Scott Evans; David B Clifford; Muraldihar Pallaki; Judith S Currier; Marlene Smryzynski Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Ann B Ragin; Ying Wu; Renee Ochs; Rachel Scheidegger; Bruce A Cohen; Robert R Edelman; Leon G Epstein; Justin McArthur Journal: Proteomics Clin Appl Date: 2010-01-04 Impact factor: 3.494
Authors: Donna C Davidson; Michael P Hirschman; Sherry L Spinelli; Craig N Morrell; Giovanni Schifitto; Richard P Phipps; Sanjay B Maggirwar Journal: J Immunol Date: 2010-11-29 Impact factor: 5.422
Authors: Kelly A Metcalf Pate; Claire E Lyons; Jamie L Dorsey; Erin N Shirk; Suzanne E Queen; Robert J Adams; Lucio Gama; Craig N Morrell; Joseph L Mankowski Journal: J Infect Dis Date: 2013-07-11 Impact factor: 5.226
Authors: Sarah E Beck; Suzanne E Queen; Kelly A Metcalf Pate; Lisa M Mangus; Celina M Abreu; Lucio Gama; Kenneth W Witwer; Robert J Adams; M Christine Zink; Janice E Clements; Joseph L Mankowski Journal: J Neurovirol Date: 2017-10-03 Impact factor: 2.643